Callahan Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$806K Buy
13,291
+804
+6% +$46.9K 0.07% 122
2025
Q4
$674K Buy
12,487
+1,407
+13% +$67.7K 0.06% 129
2025
Q3
$500K Sell
11,080
-411
-4% -$19.2K 0.04% 125
2025
Q2
$532K Buy
11,491
+3,095
+37% +$152K 0.05% 123
2025
Q1
$512K Sell
8,396
-177
-2% -$10.3K 0.05% 126
2024
Q4
$485K Buy
8,573
+1,859
+28% +$104K 0.05% 127
2024
Q3
$347K Buy
6,714
+934
+16% +$43.8K 0.03% 124
2024
Q2
$240K Buy
5,780
+1,346
+30% +$60.2K 0.03% 132
2024
Q1
$240K Buy
+4,434
New +$226K 0.03% 132
2023
Q4
Sell
-22,017
Closed -$1.28M 142
2023
Q3
$1.28M Sell
22,017
-47,818
-68% -$2.93M 0.16% 85
2023
Q2
$4.47M Sell
69,835
-25,034
-26% -$1.68M 0.54% 55
2023
Q1
$6.58M Sell
94,869
-3,912
-4% -$276K 0.85% 44
2022
Q4
$7.11M Buy
98,781
+2,040
+2% +$154K 0.97% 41
2022
Q3
$6.88M Buy
96,741
+10,783
+13% +$782K 0.99% 41
2022
Q2
$6.62M Buy
85,958
+3,273
+4% +$249K 0.88% 44
2022
Q1
$6.04M Buy
82,685
+4,306
+5% +$289K 0.69% 50
2021
Q4
$4.89M Sell
78,379
-29,813
-28% -$1.75M 0.55% 56
2021
Q3
$6.4M Buy
108,192
+4,921
+5% +$324K 0.81% 48
2021
Q2
$6.9M Buy
103,271
+12,575
+14% +$820K 0.88% 42
2021
Q1
$5.73M Buy
90,696
+21,696
+31% +$1.35M 0.78% 48
2020
Q4
$4.28M Buy
69,000
+35,858
+108% +$2.2M 0.63% 50
2020
Q3
$2M Buy
+33,142
New +$1.99M 0.33% 63

Other funds holding BMY

Callahan Advisors's BMY Position: Q1 2026 in Review

Callahan Advisors increased its Bristol-Myers Squibb (BMY) stake by 6.4% in Q1 2026, buying an estimated $46.9K and bringing the position to 13,291 shares worth $806K. The position accounts for 0.07% of the portfolio, ranked #122.

Callahan Advisors first reported a position in BMY in Q3 2020 and has held it in 22 quarters since. The position peaked at $7.11M in Q4 2022. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Callahan Advisors held 13,291 shares of Bristol-Myers Squibb worth $806K as of Q1 2026.
  • Callahan Advisors bought 804 Bristol-Myers Squibb shares in Q1 2026, an estimated $46.9K.
  • Bristol-Myers Squibb made up 0.07% of Callahan Advisors's portfolio in Q1 2026, its #122 holding.
  • Callahan Advisors first reported a position in Bristol-Myers Squibb in Q3 2020 and has held it in 22 quarters since.
  • Callahan Advisors's Bristol-Myers Squibb position peaked at $7.11M in Q4 2022.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Callahan Advisors's 13F filing for Q1 2026, filed 12 May 2026.